[1] |
KIM H W, KIM K H, SHIN A Y, et al. Investigating the appropriate adenosine deaminase cutoff value for the diagnosis of tuberculous pleural effusion in a country with decreasing TB burden[J]. Sci Rep, 2022, 12(1):7586. doi:10.1038/s41598-022-11460-w.
|
[2] |
VORSTER M J, ALLWOOD B W, DIACON A H, et al. Tuberculous pleural effusions:Advances and controversies[J]. J Thorac Dis, 2015, 7(6):981-991. doi:10.3978/j.issn.2072-1439.2015.02.18.
|
[3] |
KOO H K, MIN J, KIM H W, et al. Cluster analysis categorizes five phenotypes of pulmonary tuberculosis[J]. Sci Rep, 2022, 12(1):10084. doi:10.1038/s41598-022-13526-1.
|
[4] |
GAO L, WANG W, ZHANG Y, et al. Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion:A multicenter retrospective study[J]. Ther Adv Respir Dis, 2023,17:17534666231155747. doi:10.1177/17534666231155747.
|
[5] |
KRISHNAN V G, KUNOOR A, KEECHILATH P, et al. Diagnostic utility of pleural fluid carcinoembryonic antigen in patients with exudative pleural effusion[J]. Lung India, 2021, 38(2):139-143. doi:10.4103/lungindia.lungindia_196_20.
|
[6] |
REN Z, XU L. Role of cancer ratio and other new parameters in the differential diagnosis of malignant pleural effusion[J]. Clinics(Sao Paulo), 2021,76:e2515. doi:10.6061/clinics/2021/e2515.
|
[7] |
尉艳霞, 童朝晖, 龚娟妮, 等. 腺苷脱氨酶诊断结核性胸腔积液价值的再评价[J]. 中华结核和呼吸杂志, 2010, 33(4):273-275.
|
|
YU Y X, TONG Z H, GONG J N, et al. Evaluation of the diagnostic value of adenosine deaminase activity in tuberculous pleuritis[J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2010, 33(4):273-275. doi:10.3760/cma.j.issn.1001-0939.2010.04.012.
|
[8] |
LI Y, CHEN Z, YANG P, et al. Differentiating between tuberculous and non-tuberculous pleural effusions using the pleural fluid ratio of 10× adenosine deaminase/lactate dehydrogenase[J]. J Thorac Dis, 2023, 15(5):2627-2635. doi:10.21037/jtd-23-383.
|
[9] |
ABRAO F C, DE ABREU I R, MIYAKE D H, et al. Role of adenosine deaminase and the influence of age on the diagnosis of pleural tuberculosis[J]. Int J Tuberc Lung Dis, 2014, 18(11):1363-1369. doi:10.5588/ijtld.14.0257.
|
[10] |
ZANINI D, MANFREDI L H, PELINSON L P, et al. ADA activity is decreased in lymphocytes from patients with advanced stage of lung cancer[J]. Med Oncol, 2019, 36(9):78. doi:10.1007/s12032-019-1301-1.
|
[11] |
IBRAHIM I E, GEHAN A A, ALSHIMAA M A, et al. Role of cancer ratio and carcinogenic embryonic antigen ratio in diagnosis of pleural effusion[J]. Egyptian Journal of Chest Diseases and Tuberculosis, 2017, 66(4):671-674. doi:10.1016/j.ejcdt.2017.07.001.
|
[12] |
VERMA A, ABISHEGANADEN J, LIGHT R W. Identifying malignant pleural effusion by a cancer ratio(serum LDH:pleural fluid ADA ratio)[J]. Lung, 2016, 194(1):147-153. doi:10.1007/s00408-015-9831-6.
|
[13] |
HACKNER K, ERRHALT P, HANDZHIEV S. Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion[J]. Ther Adv Med Oncol, 2019,11:1758835919850341. doi:10.1177/1758835919850341.
|
[14] |
WANG J, LIU J, XIE X, et al. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions[J]. BMC Pulm Med, 2017, 17(1):168. doi:10.1186/s12890-017-0526-z.
|
[15] |
LEE J, PARK J E, CHOI S H, et al. Laboratory and radiological discrimination between tuberculous and malignant pleural effusions with high adenosine deaminase levels[J]. Korean J Intern Med, 2022, 37(1):137-145. doi:10.3904/kjim.2020.246.
|